Zoetis Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kristin C. Peck
- Full Time Employees
- 14,500
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 10 Sylvan Way Parsippany NJ United States of America 07054
- IPO Date
- Feb 1, 2013
- CIK
- 0001555280
- Website
- zoetis.com
- Similar Companies
- Business
- Zoetis Inc. (NYSE: ZTS) develops, manufactures and commercializes animal health medicines and vaccines, as well as a range of other animal health products and services. The company offers pharmaceuticals including anti-infectives, dermatology products, pain and sedation therapeutics, and reproductive controls; vaccines for livestock and companion animals such as dogs, cats, horses and cattle; and diagnostics, parasiticides, dermatology treatments, medicated topicals, vaccines and therapeutics for small and large animals. Zoetis provides platform technologies like the Zoetis Petcare solutions for pet owners and veterinarians, including telehealth services and data-driven insights, along with contract manufacturing and research services for biopharmaceuticals. Operating in over 100 countries with a primary focus on North America, Europe, and emerging markets in Latin America, Asia and Africa, the company targets veterinarians, livestock producers and pet owners as key customers. Founded in 2012 as a spin-off from Pfizer Inc.'s animal health business and headquartered in Parsippany, New Jersey, Zoetis has no major parent company or significant subsidiaries beyond its global operating units. In recent developments, Zoetis expanded its portfolio through the 2024 launch of new monoclonal antibody therapies for canine osteoarthritis and atopic dermatitis under the Libertym brand, formed a strategic alliance with Pharmgate Animal Health in 2025 for U.S. swine feed antibiotics distribution, and completed the acquisition of Basepaws in 2023 to bolster its pet genetics and diagnostics capabilities, reflecting ongoing innovation and market penetration efforts.
Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP
ZOETIS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ZTS
DEADLINE ALERT for CALX, AVAV, ZTS, LCID: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act: Class Action Filed Alleging Investor Harm
ZTS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Zoetis Inc. Securities Lawsuit - Contact The Gross Law Firm
Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
ZOETIS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ZTS
Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act: Class Action Filed Alleging Investor Harm
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of July 27, 2026 in Zoetis Inc. Lawsuit - ZTS
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zoetis Inc. of Class Action Lawsuit and Upcoming Deadlines - ZTS
ZOETIS INC. (ZTS) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Zoetis Inc. Investors of Upcoming Deadline
Zoetis Deadline: ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit
ZOETIS DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Zoetis Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ZTS
Zoetis Inc. (ZTS) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - Contact KTMC
Levi & Korsinsky Reminds Zoetis Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of July 27, 2026 - ZTS
Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union
Zoetis (ZTS) Stock Dips While Market Gains: Key Facts
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zoetis Inc. of Class Action Lawsuit and Upcoming Deadlines – ZTS
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zoetis Inc. of Class Action Lawsuit and Upcoming Deadlines – ZTS
ZOETIS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ZTS